Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP

NCT00076037 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: HIV CTL MEP administered with RC529-SE adjuvant
DRUG: GM-CSF

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)